SLC5A2 and type 2 diabetes mellitus: In T2D patients with a history of CV events, SGLT2-is have been shown to reduce CV mortality and hospitalization for HF [70]: among the studies that have demonstrated the cardioprotective capabilities of SGLT2-i, a mention should be made of the Canvas program, which pooled data from two different trials involving more than 10 thousand individuals with T2D and high CV risk.